Home » Newsletters » BioWorld Science

BioWorld Science

May 18, 2017

View Archived Issues

Otsuka Pharmaceutical recaps highlights of first quarter 2017

LV.CD11b.IDS for the treatment of neurocognitive impairments in an MPS II mouse model

FDA places CTP-543 phase IIa study on hold

Shire initiates phase I study of SHP-639 in intraocular hypertension and primary open-angle glaucoma

Promising clinical results seen with AAV2-AADC for AADC deficiency

rAAV9-CBA-hNAGLUop optimized gene delivery for treating MPS IIIB

FDA approves Kalydeco to treat cystic fibrosis in patients with certain residual function mutations

Omeros provides update on phase II study of OMS-721

Bristol-Myers Squibb patents casein kinase II inhibitors

Vifor presents ferroportin inhibitors

Aurinia initiates phase III study of voclosporin for lupus nephritis

Quanterix launches Simoa Neurology 4-Plex A assay to study traumatic brain injury severity

Heptares Therapeutics identifies calcitonin gene-related peptides receptor antagonists

FDA grants breakthrough therapy designation to GMI-1271 for relapsed or refractory AML

Merck & Co. discovers coagulation factor XIa and kallikrein inhibitors

Sun Pharma Advanced Research discloses estrogen receptor antagonists

Aduro Biotech expands clinical collaboration with Merck & Co.

Nanobiotix reports clinical data on potential role of NBTXR-3 in immuno-oncology

Teva nominates preclinical candidate CGRP antagonist for advancement to treat migraine

NC16A IgG4 may be a serum diagnostic marker of eosinophilic esophagitis

Specialised Therapeutics and PharmaMar enter lurbinectedin licensing agreement

miR-155 found as a predictor of methotrexate nonresponse in rheumatoid arthritis patients

Evaluation of novel anti-MUC1 (CAR)-modified T cells for the treatment of breast cancer

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...